InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights Key Clinical Progress and Reports Q3 2025 Financial Results
November 7, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company advancing treatments for rare diseases with unmet medical need, reported third quarter 2025 results and outlined upcoming milestones, including top-line Phase 2a results for SGX302 in psoriasis and an enrollment update for its confirmatory Phase 3 HyBryte(TM) study in cutaneous T-cell lymphoma (CTCL). CEO Christopher J. Schaber, PhD, […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Eyes Dermatology Market with SGX302’s Encouraging Early Results
November 6, 2025
Soligenix (NASDAQ: SNGX) is advancing its phase 2a clinical trial of SGX302, a synthetic hypericin therapy for mild-to-moderate psoriasis, building on promising phase 1/2 data. Early results from the trial show encouraging signs of safety and biological activity, highlighting SGX302’s potential as a novel, well-tolerated treatment for a chronic autoimmune skin condition affecting millions globally. […]
Soligenix Inc. (NASDAQ: SNGX) Strengthens Financial Foundation to Advance Multiple Value Drivers
November 4, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and biodefense programs, continues to fortify its financial position as it advances toward a series of pivotal and potentially transformational milestones. Following a series of strategic capital initiatives, including a $7.5 million public offering (https://ibn.fm/QKXcv), the company now reports a cash runway extending through […]
Soligenix Inc. (NASDAQ: SNGX) Strengthens Advisory Leadership in Cutaneous T-Cell Lymphoma
November 3, 2025
Soligenix (NASDAQ: SNGX), a clinical-stage biotechnology company focused on rare diseases and public health solutions, has rejuvenated its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (“CTCL”), placing fresh expertise and leadership at the center of its HyBryte(TM) development program (https://ibn.fm/ueKOC). This strategic move signals the company’s deepening commitment to advancing its pipeline agents in […]
Soligenix Inc. (NASDAQ: SNGX) Research Highlights Breakthrough in High-Temperature Vaccine Stability
October 28, 2025
Current vaccines for Ebola and similar filoviruses face a major deployment barrier: Most require storage between 2°C and 8°C throughout transport, making them vulnerable to spoilage when exposed to the high ambient heat common in many outbreak regions (https://ibn.fm/MZWfk). Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines, has published […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advances HyBryte(TM) as Potential First-Line CTCL Treatment with Promising FLASH Results
October 22, 2025
Soligenix (NASDAQ: SNGX) is continuing to build momentum in the treatment of early-stage cutaneous T-cell lymphoma (“CTCL”) through promising results from its pivotal FLASH trial and ongoing FLASH 2 confirmatory study. HyBryte(TM)—a novel, non-UV light-activated therapy using synthetic hypericin—has demonstrated statistically significant efficacy and safety, offering hope in a field where therapeutic innovation has lagged. […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Updates U.S. Medical Advisory Board to Advance Phase 3 Development of HyBryte for CTCL
October 14, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced updates to its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (CTCL) to support the ongoing Phase 3 development of HyBryte(TM) (synthetic hypericin). The board, comprised of leading dermatologic and oncologic experts, will provide strategic guidance as Soligenix advances regulatory and […]
Soligenix Inc. (NASDAQ: SNGX) Closes Multimillion-Dollar Public Offering to Fund Pipeline Through 2026
October 13, 2025
Soligenix (NASDAQ: SNGX) recently announced the closing of a $7.5 million public offering, providing the company with additional capital to advance its pipeline (https://ibn.fm/tCsub). This funding extends Soligenix’s cash runway through the end of 2026, ensuring that the company has the financial resources to reach key inflection points across its portfolio, including late-stage clinical trials […]
Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL
October 9, 2025
Cutaneous T-cell lymphoma (“CTCL”) is a rare but serious form of non-Hodgkin lymphoma that primarily affects the skin. Globally, millions suffer from CTCL, and in Europe, the annual incidence is estimated at 2.9 to 3.9 cases per million people (https://ibn.fm/ANk8X). Despite its rarity, CTCL presents a substantial unmet medical need, particularly in early-stage patients who […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reports Positive Safety Review from DMC in Ongoing Phase 3 FLASH2 Study of HyBryte for CTCL
October 7, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases, announced that its Data Monitoring Committee has completed its first review of the confirmatory Phase 3 FLASH2 study of HyBryte(TM) (synthetic hypericin) in cutaneous T-cell lymphoma, concluding there are no safety concerns and that the therapy maintains an acceptable safety profile consistent with […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Closes $7.5 Million Public Offering to Extend Cash Runway Through 2026
October 1, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced the closing of its $7.5 million public offering of 5,555,560 shares of common stock and accompanying warrants at $1.35 per share, with proceeds intended to fund R&D, commercialization, working capital, and general corporate purposes; the financing, which included participation from existing […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board to Advance HyBryte Phase 3 Study
September 30, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced the expansion of its European Medical Advisory Board to guide its confirmatory Phase 3 trial of HyBryte(TM) in early-stage cutaneous T-cell lymphoma, an 18-week study enrolling about 80 patients with top-line results expected in the second half of 2026, as the […]
Soligenix Inc. (NASDAQ: SNGX) Advances Psoriasis Trial with Encouraging Patient Results, Market Potential
September 29, 2025
Psoriasis remains a persistent challenge for millions of patients worldwide, and promising new treatments are being closely watched by the medical and investor communities alike. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and inflammatory conditions, is advancing its treatment candidate, SGX302, in a phase 2a clinical trial for mild-to-moderate psoriasis. The […]
Soligenix Inc. (NASDAQ: SNGX) Strengthens Position in CTCL Treatment with HyBryte(TM) FLASH Results
September 24, 2025
Soligenix (NASDAQ: SNGX) is continuing to build momentum in its mission to advance HyBryte(TM), a first-in-class treatment for early-stage cutaneous T-cell lymphoma (“CTCL”). That progress is supported by results from its pivotal FLASH trial and its ongoing FLASH 2 confirmatory study. Together, the studies highlight not only the efficacy of synthetic hypericin activated by safe […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Appoints Tomas J. Philipson, PhD as Strategic Advisor
September 23, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, announced the appointment of Tomas J. Philipson, PhD as a Strategic Advisor. Dr. Philipson, an expert in U.S. economic and healthcare policy with extensive academic, business, and government experience, previously served as acting chairman of the White House […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Leveraging Positive Clinical Data to Shape Pivotal SGX942 Trial
September 19, 2025
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical need. The company’s SGX942 is a novel therapeutic aimed at alleviating oral mucositis, a debilitating side effect of cancer therapy with no FDA-approved treatment. “Severe oral mucositis (‘SOM’) often necessitates hospitalization, opioid pain management […]
Soligenix Inc. (NASDAQ: SNGX) Showcases Expanding Rare Disease, Public Health Pipeline in Latest Corporate Presentation
September 9, 2025
Soligenix (NASDAQ: SNGX) has taken a bold step forward with its latest corporate presentation, offering investors and the broader biotech community a deeper look into the company’s evolving strategy and pipeline (https://ibn.fm/YGu4N). The presentation underscores Soligenix’s dual focus: pioneering therapies for rare diseases that lack adequate treatment options while simultaneously developing critical vaccines and countermeasures […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Publishes Data Demonstrating Two-Year Stability of ThermoVax Ebolavirus Vaccines
September 4, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced the publication of new data showing extended stability of its ebolavirus vaccines developed with the ThermoVax(R) platform. Bivalent and trivalent vaccines formulated from Zaire ebolavirus, Sudan ebolavirus, and Marburg marburgvirus antigens retained full potency after two years of storage at up to 40°C […]
Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Treatment with FDA Orphan Designation
September 4, 2025
Soligenix (NASDAQ: SNGX) has taken a decisive step forward in the fight against rare diseases, announcing that the FDA has granted orphan drug designation to its investigational therapy dusquetide for the treatment of Behçet’s disease (https://ibn.fm/0t1aK). This key FDA designation underscores not only the strength of recent phase 2 results but also the company’s growing […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO to Present at H.C. Wainwright Global Investment Conference
September 2, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, announced that President and CEO Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place Sept. 8–10, 2025. The on-demand presentation will be available beginning Sept. 5 at […]
Soligenix Inc. (NASDAQ: SNGX) Reports Major Clinical Trial Milestones, Strategic Progress in Rare Disease Treatment Pipeline
August 26, 2025
With pivotal phase 3 cancer trial results due in 2026 and multiple fast-tracked therapies advancing through late-stage development, Soligenix (NASDAQ: SNGX) stands at the threshold of potentially transforming treatment paradigms for rare diseases affecting millions of underserved patients worldwide. The Soligenix pipeline includes a novel photodynamic drug therapy, along with other innovative drug and vaccine […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Awarded FDA Orphan Drug Designation for Dusquetide in Behçet’s Disease
August 18, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced the U.S. FDA has granted orphan drug designation to dusquetide, the active ingredient in SGX945, for treatment of Behçet’s Disease. The designation follows a review of recent Phase 2a clinical results demonstrating biological efficacy and safety in patients. To view the full press […]
Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
August 15, 2025
With global security threats driving demand for advanced biodefense solutions, Soligenix (NASDAQ: SNGX) is advancing RiVax(R), a heat-stable recombinant vaccine candidate aimed at protecting against deadly ricin toxin exposure. Supported by proprietary stabilization technology and robust preclinical data demonstrating long-lasting immunity, SNGX’s RiVax represents both a critical public safety innovation and a significant market opportunity […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Q2 2025 Results Highlight Progress in Late-Stage Rare Disease Pipeline
August 14, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharma company developing treatments for rare diseases, reported Q2 2025 results and recent milestones. The company expects top-line Phase 2a results for SGX302 in mild-to-moderate psoriasis before year-end, along with continued updates from its investigator-initiated study of HyBryte(TM) for early-stage cutaneous T-cell lymphoma (CTCL). A confirmatory Phase 3 trial of […]
InvestorNewsBreaks – Alliance Global Partners Maintains Buy Rating, Increases Price Target as Soligenix Inc. (NASDAQ: SNGX) Advances Proprietary Clinical Programs
August 11, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted last week in a report from Alliance Global Partners (“AGP”), which maintained its Buy rating for Soligenix and raised SNGX’s price target to $10 per share. According to the report, the increase was based on the increasing valuation of HyBryte(TM) for the treatment […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in NNW Editorial on Rare Disease Innovation
August 7, 2025
Soligenix (NASDAQ: SNGX) today announced its inclusion in a NetworkNewsWire (“NNW”) editorial titled “Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators.” The article underscores the growing healthcare challenges of rare diseases among aging Americans and the urgent need for effective therapies. Soligenix is spotlighted for its HyBryte(TM) platform, a novel treatment for […]
Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy
August 7, 2025
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) — via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full […]
InvestorNewsBreaks – Soligenix, Inc. (NASDAQ: SNGX) Spotlighted in Editorial on Rare Disease Therapeutics
August 5, 2025
Soligenix (NASDAQ: SNGX) has been featured in a NetworkNewsWire editorial highlighting its progress in addressing rare diseases, particularly among aging populations. The piece emphasizes the urgent need for effective treatments as over 30 million Americans live with rare conditions, many lacking FDA-approved therapies. Soligenix’s HyBryte(TM) platform, targeting cutaneous T-cell lymphoma—a rare skin cancer affecting older […]
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
August 5, 2025
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) — via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Achieves Biological Efficacy in Phase 2a SGX945 Study for Behçet’s Disease
July 31, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing products for rare diseases, has completed its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in Behçet’s Disease, meeting the objective of demonstrating biological efficacy. In the open-label trial, SGX945 achieved a 40% improvement in the primary ulcer endpoint versus a historical placebo group from the […]
InvestorNewsBreaks – Targeting the Unmet: Soligenix Inc. (NASDAQ: SNGX) Building Portfolio for Rare Conditions
July 25, 2025
According to a recent article, “Behçet’s disease is rare, with prevalence estimates varying from 0.12 to 7.5 per 100,000 in the United States and Europe… Behçet’s disease is believed to be an autoimmune illness with both genetic and environmental components. Symptoms are most severe in young adulthood and generally ameliorate with age… Treatment involves medications […]
Soligenix Inc. (NASDAQ: SNGX) Pioneering Oral Mucositis Treatment with Novel Therapeutic, Promising Study Results
July 24, 2025
Oral mucositis, a debilitating side effect of cancer therapy with no FDA-approved treatment, continues to wreak havoc on patients undergoing cancer care, prompting an urgent need for effective interventions. Soligenix (NASDAQ: SNGX) is stepping forward with SGX942, a novel therapeutic aimed at alleviating this condition, with promising phase 3 data showing substantial improvements in the […]
Soligenix Inc. (NASDAQ: SNGX) Reports Strong Results in ‘Real-World’ Trial
July 18, 2025
Soligenix (NASDAQ: SNGX) is reporting encouraging interim outcomes from the ongoing investigator-initiated study (“IIS”) of its HyBryte(TM) (synthetic hypericin) program, under the direction of Ellen Kim, MD, director of the Penn Cutaneous Lymphoma Program. Kim is a leading enroller in Soligenix’s phase 3 FLASH study and serves as principal investigator for the confirmatory phase 3 FLASH2 trial, […]
InvestorNewsBreaks – Zacks Research Releases Updated Report as Soligenix Inc. (NASDAQ: SNGX) Eyes Upcoming ‘Key Catalysts’
July 15, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted in a July 10 Zacks Small-Cap Research report that presented a favorable analysis, noting that the company is anticipating a number of key catalysts in the second half of 2025, including progress on its current phase 3 FLASH2 trial of HyBryte(TM) for the […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Targets Multiple 2025–2026 Catalysts Across Rare Disease Pipeline
July 9, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing therapies for rare diseases with unmet medical needs, issued a shareholder update outlining key clinical and strategic milestones. President and CEO Dr. Christopher J. Schaber highlighted upcoming data readouts for lead candidates, including Phase 3 FLASH 2 results for HyBryte(TM) (synthetic hypericin) in cutaneous T-cell lymphoma expected […]
Soligenix Inc. (NASDAQ: SNGX) Highlights Encouraging Phase 3 Progress for HyBryte(TM) in Investment Webinar
July 2, 2025
In a recent webinar hosted by Allele Capital, Soligenix (NASDAQ: SNGX) executives Dr. Christopher Schaber and Dr. Christopher Pullion shared detailed updates on the company’s HyBryte(TM) (synthetic hypericin) clinical development (https://ibn.fm/dz7eO). The event offered an in-depth look at Soligenix’s ongoing confirmatory phase 3 trial for cutaneous T-cell lymphoma (“CTCL”), a rare non-Hodgkin’s lymphoma, and discussed […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advancing Novel Immunotherapy to Combat Antibiotic Resistance
June 30, 2025
Soligenix (NASDAQ: SNGX) is at the forefront of the effort as the medical community urgently seeks alternative treatments for bacterial infections in the face of escalating antibiotic resistance. The company’s SGX943 therapy “is based on dusquetide, an Innate Defense Regulator (‘IDR’) that modulates the body’s immune response rather than directly targeting bacteria. By enhancing the […]
Soligenix Inc. (NASDAQ: SNGX) Proprietary Therapy Shows Promise in Treatment of Psoriasis
June 18, 2025
Psoriasis is more than just a skin condition — it’s a lifelong autoimmune disorder that disrupts daily life with painful, inflamed patches and an emotional toll that can be just as severe as the physical symptoms. Soligenix (NASDAQ: SNGX) is at the forefront of developing innovative therapies for this condition, notably SGX302 (synthetic hypericin), a […]
Soligenix Inc. (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s Disease
June 17, 2025
Behçet’s disease is a rare, chronic autoimmune disorder characterized by inflammation of blood vessels, leading to a range of symptoms including painful mouth and genital ulcers, eye inflammation and skin lesions. With limited treatment options available, Soligenix (NASDAQ: SNGX) is at the forefront of developing innovative therapies, notably SGX945 (dusquetide), aiming to address the unmet need […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Programs, Eyes Critical Trial Results in 2025–2026
June 12, 2025
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases. The company recently announced its financial results for the first quarter of 2025 as well as accomplishments representative of Soligenix’s continued commitment to advance its pipeline of therapeutic candidates, focusing on areas with significant unmet medical needs. “Our […]